Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]-Alflutinib in Healthy Male Volunteers
NCT03941340Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Primary endpoints: Distribution of AST2818 in whole blood and plasma and whole radioactive pharmacokinetics, Quantitive analysis of whole radioactivity of excrement and 3 more. Started Apr 2019; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03941340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941340.